Defining Interactions Between the Genome, Epigenome, and the Environment in Inflammatory Bowel Disease: Progress and Prospects.
Journal article
Noble AJ. et al, (2023), Gastroenterology
Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research
Journal article
Alexander JL. et al, (2023), Gut
The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.
Journal article
Sun Y. et al, (2023), Am J Gastroenterol
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
Journal article
Shubhakar A. et al, (2023), Journal of Crohn's and Colitis
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
Journal article
Chen J. et al, (2023), Aliment Pharmacol Ther
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Journal article
Louis E. et al, (2023), Lancet Gastroenterol Hepatol
Bi-directional Mendelian randomization analysis provides evidence for the causal involvement of dysregulation of CXCL9, CCL11 and CASP8 in the pathogenesis of ulcerative colitis.
Journal article
Chen J. et al, (2022), J Crohns Colitis
Long-term temporal stability of peripheral blood DNA methylation profiles in patients with inflammatory bowel disease.
Journal article
Joustra V. et al, (2022), Cell Mol Gastroenterol Hepatol
Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
Journal article
Adams A. et al, (2022), Gut
Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
Journal article
Selim R. et al, (2022), Lancet Gastroenterol Hepatol
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
Journal article
Wellens J. et al, (2022), Gut, 71, 1919 - 1922
Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome.
Journal article
Kalla R. et al, (2022), J Crohns Colitis
Systematic Review and Meta-analysis of Peripheral Blood DNA methylation studies in Inflammatory Bowel Disease.
Journal article
Joustra V. et al, (2022), J Crohns Colitis
Patient Reported Outcomes: the ICHOM Standard Set for inflammatory bowel disease in real life practice helps quantify deficits in current care.
Conference paper
Wong D. et al, (2022), J Crohns Colitis
Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Journal article
Serra EG. et al, (2022), Nat Commun, 13
Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Journal article
Hart A. et al, (2022), United European Gastroenterology Journal, 10, 485 - 495
BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
Conference paper
Wellens J. et al, (2022), GASTROENTEROLOGY, 162, S278 - S278
PERIPHERAL BLOOD DNA METHYLATION BIOMARKERS ACCURATELY PREDICT CLINICAL- AND ENDOSCOPIC RESPONSE TO VEDOLIZUMAB IN A REAL-LIFE COHORT OF CROHNS DISEASE PATIENTS
Conference paper
Joustra VW. et al, (2022), GASTROENTEROLOGY, 162, S794 - S794
TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE
Conference paper
Wong S-Y. et al, (2022), GASTROENTEROLOGY, 162, S1004 - S1005
WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)
Conference paper
Louis E. et al, (2022), GASTROENTEROLOGY, 162, S216 - S216